BMY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BMY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2025-04-30), Bristol-Myers Squibb Co's share price is $49.22. Bristol-Myers Squibb Co's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $6.44. Hence, Bristol-Myers Squibb Co's Price-to-Free-Cash-Flow Ratio for today is 7.64.
The historical rank and industry rank for Bristol-Myers Squibb Co's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 13 years, Bristol-Myers Squibb Co's highest Price-to-Free-Cash-Flow Ratio was 379.64. The lowest was 6.25. And the median was 12.32.
Bristol-Myers Squibb Co's Free Cash Flow per Share for the three months ended in Mar. 2025 was $0.83. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $6.44.
During the past 12 months, the average Free Cash Flow per Share Growth Rate of Bristol-Myers Squibb Co was 5.60% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 0.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 6.60% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 23.20% per year.
During the past 13 years, Bristol-Myers Squibb Co's highest 3-Year average Free Cash Flow per Share Growth Rate was 69.60% per year. The lowest was -41.30% per year. And the median was 14.70% per year.
The historical data trend for Bristol-Myers Squibb Co's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial |
![]() |
![]() |
10.53 | 9.19 | 12.92 | 8.43 | 8.22 |
Bristol-Myers Squibb Co Quarterly Data | ||||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
8.89 | 6.55 | 7.61 | 8.22 | 9.47 |
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's Price-to-Free-Cash-Flow falls into.
Bristol-Myers Squibb Co's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 49.22 | / | 6.44 | |
= | 7.64 |
Bristol-Myers Squibb Co's Share Price of today is $49.22.
Bristol-Myers Squibb Co's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.44.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
Bristol-Myers Squibb Co (NYSE:BMY) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher S. Boerner | officer: EVP, Chief Commercial Officer | 21823 30TH DRIVE S, BOTHELL WA 98021 |
Samit Hirawat | officer: Chief Medical Offr., Drug Dev. | BRISTOL-MYERS SQIUBB COMPANY, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Samuels Theodore R. Ii | director | 1990 E. GRAND AVE., EL SEGUNDO CA 90245 |
Cari Gallman | officer: EVP, Corporate Affairs | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Ann Powell Judge | officer: SVP, Human Resources | BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543 |
Robert M Plenge | officer: EVP, Chief Research Officer | C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
Rupert Vessey | officer: Pres., Research & Early Dev. | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Adam Lenkowsky | officer: EVP, Chief Commercial Officer | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Giovanni Caforio | officer: EVP & Chief Commercial Officer | BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543 |
David V Elkins | officer: EVP, Chief Financial Officer | C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417 |
Deepak Bhatt | director | BRISTOL MYERS SQUIBB, 430 E. 29TH STREET, 14TH FLOOR, NEW YORK NY 10016 |
Sandra Leung | officer: Vice President and Secretary | C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164 |
Sharon Greenlees | officer: SVP & Controller | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Karin Shanahan | officer: EVP, Glob. Prod. Dev. & Supply | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Gregory Scott Meyers | officer: EVP, Chief Digital & Tech Off. | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
From GuruFocus
By Business Wire • 04-14-2025
By GuruFocus News • 04-11-2025
By GuruFocus News • 04-09-2025
By GuruFocus News • 04-14-2025
By GuruFocus News • 04-14-2025
By GuruFocus News • 04-14-2025
By GuruFocus News • 04-10-2025
By GuruFocus News • 04-19-2025
By GuruFocus News • 04-21-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.